News

Inotek has reported positive top-line results from phase 1/2 randomized, double-blind, placebo-controlled clinical trial of INO-8875, in patients with glaucoma. The study showed that the treatment with INO-8875

Insmed has declared the results of phase-II clinical trial evaluating IPLEX (mecasermin rinfabate) in patients with myotonic muscular dystrophy (MMD). The randomized, double-blind, placebo-controlled trial conducted in 13

Intercell has announced that the US Centers for Disease Control and Prevention (CDC’) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations and include IXIARO,

Zila has entered into a merger agreement with Tolmar, a privately-held pharmaceutical research, development, manufacturing and commercial operations company. Under the terms of the agreement, Tolmar will acquire

OraSure has provided update regarding the status of its application for FDA approval of an OraQuick Hepatitis C (HCV) test, and its clinical program for an OraQuick HIV-1/2

Novartis’ new study demonstrated that treatment with Afinitor (everolimus) tablets, in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy, may have the potential to

Shamrock has received a phase-I Small Business Innovation Research (SBIR) grant to develop Wide Angle X-ray Scattering (WAXS) for Drug Discovery. It is funded by the National Institute

Protalix has initiated home care treatment program for patients enrolled in the phase-III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD). The phase-III extension trial is a follow-on

AstraZeneca and Bristol-Myers’ marketing authorisation application for Onglyza (saxagliptin) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), for Onglyza. It is